Over the past decade, melanoma has led the field in new cancer treatments, with impressive
gains in on-treatment survival but more modest improvements in overall survival. Melanoma …

Drug resistance is a major challenge in cancer treatment. Emerging evidence indicates that
deregulation of YAP/TAZ signaling may be a major mechanism of intrinsic and acquired …

Cancer cells rely on dysregulated gene expression. This establishes specific transcriptional
addictions that may be therapeutically exploited. Yet, the mechanisms that are ultimately …

Melanoma is an aggressive malignancy originating from pigment-producing melanocytes.
The development of targeted therapies (MAPK pathway inhibitors) and immunotherapies …

Novel treatment approaches are needed to overcome innate and acquired mechanisms of
resistance to current anticancer therapies in cancer cells and the tumour immune …

Simple Summary Phosphatase and tensin homolog deleted on chromosome ten (PTEN) is a
multifunctional tumor suppressor with protein-and lipid-phosphatase activities. The …

As widely acknowledged, 40–50% of all melanoma patients harbour an activating BRAF
mutation (mostly BRAF V600E). The identification of the RAS–RAF–MEK–ERK (MAP kinase) …

Understanding the molecular events controlling melanoma progression is of paramount
importance for the development of alternative treatment options for this devastating disease …

Targeting MAPK pathway using a combination of BRAF and MEK inhibitors is an efficient
strategy to treat melanoma harboring BRAF-mutation. The development of acquired …

Loss of the tumor suppressor phosphatase and tensin homologue deleted on chromosome
10 (PTEN), which negatively regulates the PI3K–AKT–mTOR pathway, is strongly linked to …